Brief: XtalPi's Unit In Strategic Collaboration With Lilly To Advance Bispecific Antibody Development
05/11/2025 11:30
Nov 5 (Reuters) - XtalPi Holdings Ltd 2228.HK: UNIT IN STRATEGIC COLLABORATION WITH LILLY TO ADVANCE AI DRIVEN BISPECIFIC ANTIBODY DEVELOPMENT Further company coverage: 2228.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on XtalPi Holdings
See all newsBrief: XtalPi Announces Strategic Partnership With Potential Deal Value Over $400 Mln
Brief: Xtalpi To Repurchase Shares Up To $100 Million
Brief: XtalPi Receives Second Payment From DoveTree Under Strategic Collaboration
Brief: XtalPi Says Subsidiary Buys Structured Deposits For RMB356.1 MLN On Sept 11
Brief: Xtalpi Holdings Posts FY Profit Attributable RMB123.7 Million